Best of 2024: ASLeap: Higher Dose Secukinumab in Ankylosing Spondylitis | RheumNow
Ankylosing spondylitis (AS) patients not responding to usual dosing with secukinumab (150 mg) after 16 weeks were dose escalated to secukinumab (SEC) 300 mg, but failed to show improvement by week 52.